Company Overview
About Emulate
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the microstructure and function of human organs. Founded in 2013 as a spin-out from the Wyss Institute at Harvard University, Emulate's chips model the liver, intestine, lung, kidney, brain, and other organ systems with a fidelity that animal models and traditional cell culture cannot match. The technology was originally developed to reduce drug development attrition rates caused by poor translation from animal studies to human clinical outcomes.
Business Model & Competitive Advantage
Emulate holds a uniquely strong regulatory relationship with the FDA: its Liver-Chip is the first and only Organ-Chip accepted into the FDA's ISTAND (Innovative Science and Technology Approaches for New Drugs) program for drug-induced liver injury (DILI) evaluation, and the agency has used Emulate chips to study the safety of COVID-19 therapeutics and vaccines. This FDA recognition reflects the broader regulatory shift announced by the agency to reduce mandatory animal testing in preclinical safety studies. In June 2025 Emulate launched the AVA™ Emulation System, a self-contained instrument capable of culturing and imaging up to 96 independent Organ-Chip samples simultaneously, cutting consumable costs four-fold and in-lab labor by half compared to prior iterations. The company has raised $82M in a 2021 Series E and has chips installed in more than 150 research facilities globally.
Competitive Landscape 2025–2026
Emulate's customer base includes 17 of the top 25 global biopharmaceutical companies, as well as academic medical centers, the FDA, the European Medicines Agency, and even the International Space Station for microgravity research. The company has expanded its technology platform with Brain-Chip R1 (launched November 2025 with FUJIFILM Cellular Dynamics) and the Chip-R1™ Rigid Chip, designed to minimize drug absorption and enhance biological modeling accuracy. As the regulatory momentum around New Approach Methodologies (NAMs) accelerates, Emulate is positioned as the reference platform for human-relevant preclinical safety and efficacy testing.
Key Differentiators
Market Leader
Emulate is recognized as a market leader in the Life Sciences & BioTech sector, demonstrating strong industry presence and customer trust.
Frequently Asked Questions
Similar Brands
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Regeneron
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m
Pliant Therapeutics
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero
Compare Emulate with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Emulate? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Emulate Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Emulate vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →